Neural Regeneration Research ›› 2025, Vol. 20 ›› Issue (4): 1092-1093.doi: 10.4103/1673-5374.391335

Previous Articles     Next Articles

Anti-amyloid antibodies in Alzheimer’s disease: what did clinical trials teach us?

Danko Jeremic, Lydia Jiménez-Díaz* , Juan D. Navarro-López*   

  1. NeuroPhysiology & Behavior Lab, University of Castilla-La Mancha, Biomedical Research Center (CRIB), School of Medicine of Ciudad Real, Ciudad Real, Spain
  • Online:2025-04-15 Published:2024-07-01
  • Contact: Juan D. Navarro-López, PhD, Juan.Navarro@uclm.es; Lydia Jiménez-Díaz, PhD, Lydia.Jimenez@uclm.es.
  • Supported by:
    This work was supported by grants PID2020–115823- GB100 funded by MCIN/AEI/10.13039/501100011033, and SBPLY/21/180501/000150 funded by JCCM/ERDF - A way of making Europe, and 2022-GRIN-34354 grant by UCLM/ERDF intramural funding to LJD and JDNL. DJ held a predoctoral fellowship granted by UCLM/ESF “Plan Propio de Investigación.”

Abstract: Although many causes of Alzheimer’s disease (AD) may exist, both the original amyloid cascade and tau hypotheses posit that abnormal misfolding and accumulation of amyloid-β (Aβ) and tau protein is the central event causing the pathology. However, that conclusion could be only partly true, and there is conflicting evidence about the role of both proteins in AD, being able to precede and influence one another. Some researchers argue that these proteins are mere executors rather than primary causes of pathology. Therefore, there have been continuing refinements of both hypotheses, with alternative explanations proposed. Aβ and tau proteins may be independently involved in specific neurotoxic pathways; yet there may be other crucial processes going on in early AD. Moreover, accumulating evidence suggests that Aβ and tau act synergistically, rather than additively in disease onset (Jeremic et al., 2021, 2023a).